UNSPSC 51372305: Fentanyl

This classification denotes an opioid receptor agonist with the molecular formula C22H28N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier UF599785JZ, chemically known as propionanilide, n-(1-phenethyl-4-piperidyl)- but generally known as fentanyl, which bears US NIH Compound Identifier 3345. European Medicines Agency schedules Fentanyl in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07597MIG. The term FENTANYL is an International Non-Proprietary Name.

UNSPSC 51372305 Fentanyl is a Commodity code nominally for fentanyl products themselves, but the recent state and local solicitations show that jurisdictions are actually buying fentanyl-related education, training, and harm-reduction services, along with naloxone and drug deactivation systems. The work spans substance abuse prevention education delivered to diverse populations—adults, families, youth, school staff, law enforcement, and community organizations—as well as naloxone administration training and distribution, community outreach, and technical assistance to other agencies. Counties and health authorities are the primary issuing bodies, with a focus on underserved populations at higher risk of substance use disorders.

Activity appears concentrated in California and Florida. The County of Orange Health Care Agency in California issued an RFP for Fentanyl Education and Naloxone Training Services with a total program budget of $700,000 for the initial contract year, requiring minimum 45-minute educational and training sessions, mini trainings with naloxone distribution, and participation in community outreach events, with proposals due April 9, 2026. Seminole County, Florida solicited an IFB (Solicitation Number IFB60459723LAS) for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through quarterly deliveries, with a response deadline of July 26, 2023, under a two-year contract with one-year renewal option. The Orange County RFP includes OCLSB and DVBE set-asides with five percent cost deductions and preferences. A Texas Health and Human Services Commission RFI (posted April 3, 2026) sought vendor capabilities for a Direct-to-Manufacturer Prescriptions program but functions as early market intelligence rather than a binding procurement vehicle. Minnesota's MMCAP generic pharmaceutical RFP (due March 26, 2026) targets multi-state cooperative purchasing and does not align closely with the fentanyl code's nominal scope.